IONS
$72.33
Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pan...
Recent News
Hedge Fund Boone Capital Initiated a Stake in HealthEquity. Is the Stock a Buy?
HealthEquity delivers cloud-based healthcare savings solutions to employers and individuals, with a broad client network across the U.S.
Ionis Priority Review And DAWNZERA Data Reframe Rare Disease Growth Story
Ionis Pharmaceuticals received FDA Priority Review for its supplemental New Drug Application for olezarsen, targeting severe hypertriglyceridemia and reduction of acute pancreatitis risk. The company is presenting new Phase 3 data for DAWNZERA, its RNA targeted therapy for hereditary angioedema, at a major medical conference. These updates highlight important clinical and regulatory milestones for Ionis and patients living with serious rare conditions. Ionis Pharmaceuticals, listed as...
Ionis Pharmaceuticals CEO Teases Late-June Olezarsen Launch After FDA Priority Review Acceptance
Ionis Pharmaceuticals (NASDAQ:IONS) CEO Brett Monia told investors at Oppenheimer’s 36th Annual Healthcare Life Sciences Conference that the company received FDA acceptance of its supplemental NDA for olezarsen in severe hypertriglyceridemia (sHTG), including priority review and a June 30 PDUFA date
Olezarsen Priority Review and Expanding Rare Disease Franchise Could Be A Game Changer For Ionis (IONS)
In recent weeks, Ionis Pharmaceuticals announced that the FDA accepted a Priority Review for olezarsen in severe hypertriglyceridemia, released 2026 revenue guidance of US$800 million to US$825 million, and reported 2025 results showing revenue rising to US$944 million with a full-year net loss of US$381 million. The company also highlighted growing commercial traction for TRYNGOLZA and DAWNZERA and new DAWNZERA data in hereditary angioedema, underlining its shift into a broader...
Needham Lifts PT on Ionis Pharmaceuticals (IONS) to $103 From $90
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) is one of the best strong buy healthcare stocks to invest in. Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) released its fiscal Q4 and full-year 2025 earnings on February 25, reporting that total revenue for the year ended December 31, 2025, was $944 million compared to $705 in the previous year, considerably surpassing expectations […]